Xcellerex, Inc. and Humacyte, Inc. have entered into a strategic collaboration under which Xcellerex will develop a manufacturing process enabling the production of Humacyte’s lead regenerative drug product using its XDR single-use bioreactor system. Humacyte’s product is a large vascular graft using the company’s platform technology for engineering human, extracellular matrix-based tissues that have properties similar to native tissues. The grafts will first be used for arterio-venous acces...